Harnessing the Potential of Dual Inhibition: Targeting NLRP3 & NLRC4 Inflammasomes for Therapeutic Intervention

Time: 9:00 am
day: Day 1


  • Revealing the collaboration between NLRP3 and NLRC4 inflammasomes in triggering inflammation linked to lupus, macular degeneration, Alzheimer’s, and multiple sclerosis
  • Demonstrating the efficacy of inflammasome blockade in animal models of macular degeneration and lupus patients, promising disease prevention and inflammation reduction
  • Exploring Phase 1 trial initiation for evaluation of Kamuvudine-8 in Geographic Atrophy